|
Robert Guttendorf, Vice President, Pharmacology & Experimental Therapeutics, has extensive experience applying his pharmacokinetic (PK), pharmacodynamic (PD), and drug metabolism (DM) expertise to all phases of drug discovery and development. He received a B.S. in Pharmacy from West Virginia University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky. Dr. Guttendorf has directed PK and ADME support for Discovery through NDA and post-marketing across a variety of therapeutic areas. He has held various positions of increasing responsibility in the PK/PD/DM Departments of Parke-Davis Pharm. Research and Pfizer Global R&D, including Director of Discovery and Preclinical Development, and Global Scientific Strategy Advisor. Most recently he was Vice President of Pharmacology and Biopharmaceutics at Advancis Pharmaceutical Corp., where he oversaw preclinical and clinical pharmacology. He has been involved in numerous IND filings and three successful NDAs/MAAs. His scientific interests include streamlining early discovery ADME screening; optimizing the impact of preclinical PK/DM data on clinical development and regulatory filings; biomarkers in drug discovery and development; and the role of pharmacogenetics and other factors in controlling drug disposition. He has presented and published numerous papers on various topics in bioanalysis, pharmacokinetics, and drug metabolism. He is a registered pharmacist. | 